Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan diseases and neurology, announced today that it has closed the sale of its pediatric portfolio of assets with AYTU BioScience, Inc. (“AYTU”) in a deal valued in excess of $43 million including the assumption of various liabilities and product-related obligations. The consideration includes a combination of cash and Aytu preferred stock (the “shares”) totaling $17 million and the assumption of Cerecor’s outstanding payment obligations payable to Deerfield CSF, LLC in the amount of $15 million (“Deerfield Note”) and certain other liabilities in excess of $11 million, providing non-dilutive cash generation for Cerecor. The funds from the transaction, coupled with the removal of the aforementioned short-term obligations, extend the runway toward NDA submission of CERC-801 and its associated Priority Review Voucher (PRV).
Dr. Simon Pedder, Executive Chairman of the Board, commented, “We are pleased to have closed this deal quickly. We are moving just as quickly to expediate our fast-to-market pipeline in orphan diseases. The CERC-800s series have the potential to be the first to market treatment for Congenital Disorders of Glycosylation and will be our first approved products for commercialization.”>
Deal Components
- Overall deal valued in excess of $43 million as a composite of $17 million in cash and preferred stock ($4.5 million in cash and 12.5 million in shares of Aytu convertible preferred stock), the assumption of the Deerfield Note of $15 million, the assignment of the existing royalty obligations coupled with various commercial accruals of $11 million.
- Cash has been paid, and the Shares were issued at closing; the Shares are subject to customary lock-ups and are convertible to common shares following Aytu stockholder approval and immediately prior to their sale or distribution.
- The Pediatric Portfolio includes the following five product lines: Aciphex® Sprinkle™, Cefaclor for Oral Suspension, Karbinal® ER, Flexichamber™, Poly-Vi-Flor® and Tri-Vi-Flor™.
- Aytu plans to hire Cerecor’s Pediatric commercial infrastructure and sales force, inclusive of hiring Matt Phillips, Cerecor’s Chief Commercial Officer, as Aytu’s Executive Vice President of Commercial Operations, following his separation from Cerecor at closing.
- Aytu assumed all obligations under the Deerfield Note, associated with the Pediatric Portfolio of products.
- Aytu assumed all contractual obligations under the existing license agreements and the assumption of certain liabilities associated with the Pediatric Portfolio.
Source: Globe News Wire
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.